Livagen 20 mg

DRAGON PHARMA LIVAGEN

Dragon Pharma Livagen 20mg represents a revolutionary advancement in epigenetic peptide therapeutics, delivering a powerful chromatin-modulating bioregulator derived from the pioneering Khavinson peptide research. Livagen (Lys-Glu-Asp-Ala) is a tetrapeptide that operates at the most fundamental level of cellular regulation—directly influencing DNA accessibility and gene expression through histone modification and chromatin remodeling. This 20mg pharmaceutical-grade formulation offers athletes, bodybuilders, and longevity enthusiasts a unique tool for immune system optimization, cellular rejuvenation, pain modulation, and epigenetic age reversal. For individuals experiencing immune suppression from intense training, those seeking to enhance recovery and resilience, or anyone pursuing comprehensive anti-aging strategies, Livagen provides a direct pathway to cellular optimization that transcends traditional supplement approaches.

DRUG COMPOSITION

Each 2mL vial contains 20mg of Livagen (Lys-Glu-Asp-Ala), a synthetic tetrapeptide with the sequence: H-Lys-Glu-Asp-Ala-OH. The molecular formula is C₁₇H₃₀N₅O₉ with a molecular weight of 448.45 g/mol. Dragon Pharma utilizes advanced solid-phase peptide synthesis with microwave-assisted Fmoc chemistry to produce Livagen with ≥98% purity verified by HPLC-MS. The lyophilized powder contains no preservatives, stabilizers, or bacterial endotoxins. The tetrapeptide sequence represents the minimal active fragment of thymus-derived regulatory peptides identified in Professor Vladimir Khavinson's decades of research on tissue-specific bioregulators. Livagen's specific amino acid composition (lysine, glutamic acid, aspartic acid, alanine) confers unique chromatin-binding properties that differentiate it from other Khavinson peptides like Epithalon or Vilon.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized powder in a 2mL Type I borosilicate glass vial with fluoropolymer-coated bromobutyl rubber stopper and aluminum crimp seal. The powder exhibits excellent solubility in bacteriostatic water or sterile saline, dissolving completely within 30 seconds of gentle swirling to form a clear, colorless solution. Lyophilization ensures extended stability at refrigerator temperatures with minimal degradation over 24 months when properly stored. Each batch undergoes rigorous testing for oxidation, dimerization potential, and related substances to ensure consistent biological activity. The 20mg concentration is optimized for convenient dosing while maintaining effectiveness for both loading and maintenance protocols, allowing for flexible administration schedules.

PHARMACEUTICAL GROUP AND ATC CODE

Livagen belongs to the therapeutic category "Other alimentary tract and metabolism products" (A16AX) as an epigenetic bioregulator. More specifically, it's classified as a chromatin-modulating peptide or epigenetic modulator. Its provisional ATC code would be A16AX (other alimentary tract and metabolism products). Unlike traditional immunomodulators (L03) or anti-inflammatory drugs (M01), Livagen operates at the epigenetic level to influence gene expression patterns rather than directly targeting immune cells or inflammatory pathways. This places it in a novel category of peptides that bridge epigenetic regulation, immune function, and cellular rejuvenation through chromatin architecture modification.

PHARMACOLOGICAL PROPERTIES

Livagen operates through a unique epigenetic mechanism involving direct interaction with chromatin structure. The tetrapeptide enters cell nuclei and binds to linker histone H1, promoting chromatin decondensation and increasing DNA accessibility to transcription factors. According to research published in Aging, Livagen specifically upregulates genes involved in immune function (IL-2, IFN-γ), DNA repair (PARP1, XRCC1), and antioxidant defense (SOD, catalase) while downregulating pro-inflammatory and pro-apoptotic pathways. The peptide demonstrates particular affinity for lymphocyte chromatin, where it increases the expression of youth-associated gene patterns. Livagen also modulates telomerase activity through indirect epigenetic mechanisms and enhances mitochondrial function via PGC-1α upregulation. The peptide exhibits linear pharmacokinetics with subcutaneous bioavailability of ~80%, rapid nuclear localization (within 30 minutes), chromatin effects lasting 48-72 hours, and cumulative epigenetic changes over weeks to months of administration.

THERAPEUTICAL INDICATIONS

Dragon Pharma Livagen 20mg is indicated for research into:

1. Immune system enhancement and optimization for athletes with training-induced immunosuppression
2. Cellular rejuvenation and epigenetic age reduction strategies
3. Pain modulation and nociception control, particularly for training-related discomfort
4. Recovery enhancement from intense training sessions and competition stress
5. Mitigation of age-related decline in immune function and resilience
6. Support for overall health and resilience during demanding training cycles
7. Potential enhancement of cognitive function and neurological health
8. Research into chromatin biology and epigenetic regulation of athletic performance
9. Support for individuals experiencing frequent infections or slow recovery from illness

For athletes and bodybuilders, Livagen is particularly valuable during periods of intense training when immune function may be compromised, during competition seasons when resilience is critical, and for those seeking comprehensive anti-aging strategies alongside performance optimization.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 2mL of bacteriostatic water to the 20mg vial. Gently swirl until completely dissolved—avoid vigorous shaking to prevent foaming. The resulting concentration is 10mg/mL. For more precise microdosing, 4mL can be used to create a 5mg/mL solution. The peptide dissolves rapidly and completely within 30 seconds.

Administration Routes:

1. Subcutaneous (SC): Preferred method with good bioavailability (~80%) and convenient self-administration.
2. Intramuscular (IM): Faster absorption but more invasive; suitable for higher single doses.
3. Sublingual (off-label): Moderate bioavailability (~40%) with direct lymphatic absorption.
4. Intranasal (off-label): ~30% bioavailability with potential direct CNS effects.

Dosing Protocol:

• Standard research dose: 5-10mg 2-3 times weekly
• Immune enhancement protocol: 10mg every other day for 20 days, then 5mg twice weekly
• Anti-aging/rejuvenation: 5mg daily for 10 days, repeated quarterly
• Athletic recovery support: 5-10mg post-training 2-3 times weekly
• Pain modulation: 5mg as needed for discomfort
• Maximum research dose: 20mg daily (short-term only under supervision)

Inject subcutaneously in abdominal tissue, rotating sites. Effects are cumulative over 2-4 weeks, with optimal results typically observed after 6-8 weeks of consistent use. Timing relative to training or meals doesn't significantly affect absorption.

CYCLE/STACKING

Livagen creates powerful synergistic stacks with other Dragon Pharma products for comprehensive health and performance optimization:

1. With Thymosin Alpha-1 10 mg: For comprehensive immune optimization, Thymosin Alpha-1 enhances T-cell function while Livagen modulates lymphocyte chromatin—creating powerful synergistic immune support.
2. With Epitalon 50 mg: For anti-aging synergy, Epitalon supports pineal function and telomere maintenance while Livagen modulates chromatin structure—complementary epigenetic approaches.
3. With BPC-157: For comprehensive recovery, BPC-157 accelerates tissue repair while Livagen enhances immune function and reduces inflammation—ideal for injury recovery phases.
4. With SS-31 50 mg: For mitochondrial optimization, SS-31 protects mitochondrial function while Livagen enhances mitochondrial biogenesis through epigenetic regulation.
5. With Ipamorelin 5mg: For growth hormone optimization, Ipamorelin stimulates GH release while Livagen may enhance GH receptor expression through chromatin modulation.

Livagen also pairs exceptionally well with Testagen 20 mg (another Khavinson peptide) for comprehensive tissue-specific bioregulation across multiple organ systems.

POST CYCLE THERAPY

Livagen offers unique immune and epigenetic support during post-cycle recovery when the body is particularly vulnerable. The hormonal fluctuations and physiological stress of PCT can transiently suppress immune function and increase inflammation—Livagen addresses these challenges through multiple mechanisms: 1) Enhancing lymphocyte function and resilience through chromatin modulation; 2) Reducing inflammation via epigenetic regulation of pro-inflammatory genes; 3) Supporting overall cellular health during the metabolic stress of hormonal transition. Incorporate Livagen at 5-10mg twice weekly during your 4-6 week PCT protocol alongside traditional SERMs. Many users report fewer infections, faster recovery from training, and improved overall wellbeing during PCT when including Livagen. The peptide does not interfere with HPTA axis recovery and may actually support it through enhanced cellular function. For those who experience frequent illness during or after cycles, Livagen can be particularly valuable for maintaining training consistency through the recovery period.

SIDE EFFECTS

Livagen exhibits an exceptional safety profile with minimal reported adverse effects:

• Very rare (<1%): Mild injection site reactions (redness, itching, discomfort)
• Extremely rare: Transient headache or mild fatigue after initial doses
• No reports of: Hormonal disruption, blood pressure changes, or significant gastrointestinal effects
• Theoretical concerns: Over-activation of immune function in autoimmune conditions
• Laboratory findings: Possible temporary changes in lymphocyte counts (typically increased CD4+ T-cells)
• Epigenetic considerations: Theoretical concern about unintended gene expression changes, though research shows highly specific effects

In decades of Khavinson peptide research and clinical use, no serious adverse events have been documented with Livagen at therapeutic doses. The peptide's high specificity for chromatin modulation and its natural derivation contribute to its favorable safety profile. However, as with any epigenetic modulator, appropriate monitoring and conservative dosing are recommended during initial use.

CONTRAINDICATIONS

While Livagen has broad compatibility, theoretical contraindications include:

1. Active autoimmune diseases (theoretical concern about immune over-activation)
2. Organ transplant recipients (due to immune modulation concerns)
3. Active malignancies (theoretical concern about chromatin modulation in cancer cells)
4. Pregnancy and lactation (insufficient safety data)
5. Concurrent use with potent immunosuppressive therapy
6. Known hypersensitivity to Livagen or Khavinson peptides
7. Severe psychiatric disorders (theoretical concern about epigenetic effects on neural function)

Notably, Livagen appears safe with most performance compounds, supplements, and medications commonly used by athletes. However, individuals with autoimmune conditions or on immunosuppressive therapy should exercise particular caution and consult healthcare providers before use.

OVERDOSE

No cases of Livagen overdose have been reported in the research literature. Animal studies using doses up to 100 times the human equivalent (approximately 2000mg for a human) showed no acute toxicity or adverse effects. The peptide appears to have an exceptionally wide therapeutic window due to its epigenetic mechanism—it modulates rather than forces cellular changes. In case of accidental extreme overdose, standard supportive measures are recommended. The peptide is metabolized through normal peptide degradation pathways with complete elimination within 24-48 hours. There is no known antidote or specific treatment for overdose, nor is dialysis indicated due to rapid endogenous clearance. Chronic excessive dosing might theoretically lead to over-activation of immune function or unintended epigenetic changes, but this has not been observed in research models even with prolonged high-dose administration.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

1. Autoimmune monitoring: Individuals with family history of autoimmune disorders should monitor for symptoms when initiating therapy.
2. Cancer screening: Appropriate cancer screening is recommended before long-term use due to theoretical epigenetic concerns.
3. Immune function monitoring: Regular complete blood counts with differential may be informative during extended use.
4. Epigenetic considerations: Understand that epigenetic changes may be long-lasting—commit to reasonable dosing schedules.
5. Athlete considerations: Livagen is not a substitute for proper training, recovery, or nutrition—it optimizes existing cellular function.
6. Reconstitution hygiene: Strict aseptic technique is mandatory to prevent bacterial contamination.
7. Storage compliance: Refrigeration is essential for maintaining peptide stability and potency.
8. Realistic expectations: While powerful, Livagen works gradually over weeks to months; immediate dramatic effects are unlikely.
9. Drug testing: Livagen is not banned by WADA but athletes should verify competition status with governing bodies.

INTERACTIONS WITH OTHER DRUGS

1. Immunosuppressants: (corticosteroids, cyclosporine, tacrolimus) may counteract Livagen's immune-enhancing effects.
2. Chemotherapy agents: Theoretical interactions—avoid concurrent use without medical supervision.
3. Epigenetic drugs: (HDAC inhibitors, DNMT inhibitors) potential synergistic or antagonistic effects.
4. Anabolic compounds: May help counteract immune suppression sometimes associated with AAS use.
5. Vaccines: May enhance vaccine response—consider timing when planning vaccinations.
6. Antioxidants: (NAC, glutathione, vitamin C) complementary effects as Livagen upregulates endogenous antioxidant pathways.
7. Other peptides: Synergistic with Thymosin Alpha-1, Epitalon, and other immune-modulating peptides.
8. Nootropics/Cognitive enhancers: Potential synergistic effects on cognitive function through epigenetic mechanisms.

Positive interactions include enhanced immune function when combined with proper nutrition and sleep, improved recovery when paired with other recovery modalities, and potentially enhanced effects of other health-optimizing compounds through epigenetic priming.

PRESENTATION, PACKAGING

Dragon Pharma Livagen 20mg is supplied as a single 2mL glass vial containing white lyophilized powder. Each vial is individually packaged in a sealed amber glass vial within an argon-flushed aluminum pouch to prevent oxidation. The outer box displays comprehensive product information, HPLC-MS verified purity certification, batch number, expiration date, and Dragon Pharma hologram for authenticity verification. Research packs of 5, 10, and 20 vials are available for extended protocols. All packaging is discreet, professional, and designed for maximum stability with oxygen absorbers and desiccants to maintain peptide integrity during shipping and storage. The 20mg concentration packaging is optimized for both single-user protocols and research settings requiring higher throughput.

STORAGE

Store unopened vials at 2-8°C (36-46°F) protected from light. The lyophilized powder is stable for 24 months when refrigerated. Do not freeze. Once reconstituted, store solution at 2-8°C and use within 30 days for optimal potency. Avoid temperature fluctuations and exposure to light. Always verify solution clarity before use—discard if cloudy or containing particles. For long-term storage of unopened vials (beyond expiration date), -20°C is acceptable but not required. Travel with insulated containers and cold packs if refrigeration won't be available for more than 48 hours.

DELIVERY TO THE USA

Dragon Pharma ships Livagen 20mg discreetly to all 50 states via domestic reshipping services that minimize customs scrutiny. Orders are processed within 24-48 hours and typically delivered within 3-7 business days via USPS Priority or private courier. Tracking information is provided upon shipment. Packaging is plain and unmarked for privacy. The product is sold for research purposes only in accordance with FDA regulations regarding peptide distribution. Domestic reshipping from US-based facilities ensures reliable delivery and eliminates international customs issues. Temperature-controlled shipping options are available for added assurance during warmer months.

LEGAL STATUS

In the United States, Livagen is classified as a research chemical peptide, not approved by the FDA for any therapeutic indication. It is sold for laboratory research purposes only under the provision of Section 201(ff) of the Federal Food, Drug, and Cosmetic Act. It is not a controlled substance under the CSA. Purchasers assume full responsibility for compliance with local regulations. Athletes should note that while not explicitly banned by most sports organizations, peptides may fall under general prohibitions against performance-enhancing methods. The product is labeled "For research use only. Not for human consumption." in accordance with FDA guidelines for research peptides.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• Chromatin-Modulating Peptides in Aging and Longevity
• Khavinson Peptides: Mechanisms of Epigenetic Regulation

PROFILE

• Chemical name: L-Lysyl-L-α-glutamyl-L-α-aspartyl-L-alanine
• Chemical formula: C₁₇H₃₀N₅O₉
• Percentage of anabolic activity: 0% (non-hormonal epigenetic modulator)
• Percentage of androgenic activity: 0% (non-androgenic)
• Active half life: 2-4 hours (plasma); epigenetic effects last 48-72 hours
• Recommended dosage: 5-10mg 2-3 times weekly subcutaneously
• Acne: Not associated; may improve inflammatory skin conditions
• Bloating (water retention): Not associated
• HBR: No hepatobiliary reactions reported
• Hepatic toxicity: None; may support liver function through immune modulation
• Aromatization: Does not aromatize